Maladies Hémorragiques Constitutionnelles

2023

Alessi MC, Coxon C, Ibrahim-Kosta M, Bacci M, Voisin S, Rivera J, Greinacher A, Raster J, Pulcinelli F, Devreese KMJ, Mullier F, McCormick AN, Frontroth JP, Pouplard C, Sachs UJ, Diaz I, Bermejo N, Camera M, Fontana P, Bauters A,Stepanian A, Cozzi MR, Sveshnikova AN, Faille D, Hollon W, Chitlur M, Casonato A, Lasne D, Lavenu-Bombled C, Fiore M, Hamidou B, Hurtaud-Roux MF, Saultier P, Goumidi L, Gresele P, Lordkipanidzé M. Multicenter evaluation of light transmission platelet aggregation reagents: communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost. 2023 Sep;21(9):2596-2610

Guillet B, Hassoun A, Wibaut B, Harroche A, Biron-Andréani C, Repesse Y, d’Oiron R, Tardy B, Pan Petesch B, Chamouni P, Gay V, Fouassier M, Pouplard C, Martin C, Catovic H, Delavenne X. A French Real-World Evidence Study Evaluating the Efficacy, Safety, and Pharmacokinetic Parameters of rVIII-SingleChain in Patients with Hemophilia A Receiving Prophylaxis. Thromb Haemost. 2023 May;123(5):490-500.

2022

• rFVIII-Fc in severe haemophilia A: The incentive switch in case of high risk of joint bleedings. Valérie Horvais, Matthieu Wargny, Yohann Repessé, Benoît Guillet, Philippe Beurrier, Laurent Ardillon, Brigitte Pan-Petesch, Vincent Cussac, Marc Trossaërt. 2022 Oct;52(10):e13824. doi: 10.1111/eci.13824. Epub 2022 Jun 27.
• Ternisien C, Lasne D, Grand F, Harzallah I, Jeanpierre E, Repesse Y, Ryman A, Sapin AF, Voisin S, Nougier C, Pouplard C; French study group on laboratory management of bleeding disorders (BIMHO Group-GFHT). Impact of aPTT reagents on measurement of a PEGylated recombinant FVIII (Adynovi®/Adynovate®): A French multicentric field assay study. Int J Lab Hematol. 2022 Apr;44(2):e55-e59.
• Tardy B, Lambert T, Chamouni P, Montmartin A, Trossaert M, Claeyssens S, Berger C, Ardillon L, Gay V, Delavenne X, Harroche A, Chelle P. Revised terminal half-life of nonacog alfa as derived from extended sampling data: A real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis. Haemophilia. 2022 Jul;28(4):542-547. doi: 10.1111/hae.14560. Epub 2022 Apr 14

2021

Baglo T, Pouplard C, Valentin JB, Guéry EA, Gruel Y, Vayne C. Acquired platelet defect associated with gabapentin treatment: a case-report. Platelets. 2021 Aug 18;32(6):846-849.

Sannié T, de Moerloose P; AFATH. How to implement medical and patient associations in low-income countries: A proposition from the African French Alliance for the Treatment of Haemophilia (AFATH). Haemophilia. 2021 Mar;27(2):261-269. (Auteur associé)

2020

• Bleeding complications during pregnancy and delivery in haemophilia carriers and their neonates in Western France: An observational study. Nau A, Gillet B, Guillet B, Beurrier P, Ardillon L, Cussac V, Guillou S, Raj L, Trossaërt M, Horvais V, Bayart S, Potin J, Rose J, Macchi L, Couturaud F, Lacut K, Pan-Petesch B.Haemophilia. 2020 Nov;26(6):1046-1055. doi: 10.1111/hae.14117. Epub 2020 Aug 25.PMID: 32842170 
• Evaluation of functional assays for the diagnosis of heparin induced thrombocytopenia using 5B9, a monoclonal IgG that mimics human antibodies. Vayne C, Guéry EA, Charuel N, Besombes J, Lambert WC, Rollin J, Gruel Y, Pouplard C. J Thromb Haemost. 2020 Jan 29.
• [Therapeutic antibodies in hemostasis. From the past to the future]. Gruel Y, Kizlik-Masson C, Lenting P. Med Sci (Paris). 2019 Dec Epub 2020 Jan 6

• Nougier C, Jeanpierre E, Ternisien C, Proulle V, Hezard N, Pouplard C, Lasne D; With contributions from the Working Group on Biology of Haemorrhagic Disorders (BIMHO, Under the Aegis of GFHT). Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals). Eur J Haematol. 2020 Dec;105(6):675-681.

   

• Jeanpierre E, Pouplard C, Lasne D, Le Cam Duchez V, Eschwege V, Flaujac C, Galinat H, Harzallah I, Proulle V, Smahi M, Sobas F, Stepina N, Toulon P, Voisin S, Ternisien C, Nougier C; French Study Group on the Biology of Hemorrhagic Diseases (the BIMHO group). Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT). Eur J Haematol. 2020 Aug;105(2):103-115.

   

• Allard Q, Djerada Z, Pouplard C, Repessé Y, Desprez D, Galinat H, Frotscher B, Berger C, Harroche A, Ryman A, Flaujac C, Chamouni P, Guillet B, Volot F, Szymezak J, Nguyen P, Cazaubon Y. Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life? Pharmaceutics. 2020 Apr 21;12(4):380.

   

• Pouplard C, Sattler L, Ryman A, Eschwege V, De Maistre E, Flaujac C, Szymezak J, Grand F, Repesse Y, Galinat H, Donnard M, Ternisien C, Iorio A, Chelle P, Jeanpierre E; ‘Biology Study Group on Haemorrhagic Diseases’ (Group BIMHO – GFHT). Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates. Haemophilia. 2020 Mar;26(2):282-289.

   

• Nau A, Gillet B, Guillet B, Beurrier P, Ardillon L, Cussac V, Guillou S, Raj L, Trossaërt M, Horvais V, Bayart S, Potin J, Rose J, Macchi L, Couturaud F, Lacut K, Pan-Petesch B. Bleeding complications during pregnancy and delivery in haemophilia carriers and their neonates in Western France: An observational study. Haemophilia. 2020 Nov;26(6):1046-1055.

2019

• Use of von Willebrand Factor Concentrate in Inherited von Willebrand Disease: How Often Is It Useful to Add Factor VIII? Drillaud N, Ardillon L, Ternisien C, Valentin JB, Fouassier M, Gillet B, Gruel Y, Sigaud M, Horvais V, Bene MC, Trossaërt M. Transfus Med Rev. 2019 Nov 1

• Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra® ): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP). Susen S, Gruel Y, Godier A, Harroche A, Chambost H, Lasne D, Rauch A, Roullet S, Fontana P, Goudemand J, de Maistre E, Chamouard V, Wibaut B, Albaladejo P, Négrier C. Haemophilia. 2019 Sep

• Multicentre evaluation of CK Prest® for assaying plasma levels of factor IX fused with albumin (Idelvion® ). Pouplard C, Galinat H, Ternisien C, Blanc Jouvan F, De Maistre E, Duchemin J, Flaujac C, Hézard N, Grand F, Le Cam-Duchez V, Marlu R, Mourey G, Nedelec F, Pineau-Vincent F, Repesse Y, Stépanian A, Szymezak J, Voisin S, Voyer AL, Jeanpierre E, Lasne D; French Study Group on Laboratory Management of bleeding disorders (BIMHO group). Haemophilia. 2019 Sep

• Estimation of Nuwiq® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study. Tiefenbacher S, Albisetti M, Baker P, Kappert G, Kitchen S, Kremer Hovinga JA, Pouplard C, Scholz U, Ternisien C, Borgvall C, Vicente T, Belyanskaya L, Walter O, Oldenburg J; Nuwiq Field Study Participating Laboratories. Haemophilia. 2019 Jul

• Frequency and Clinical Impact of Platelet Factor 4-Specific Antibodies in Patients Undergoing Extracorporeal Membrane Oxygenation. Vayne C, May MA, Bourguignon T, Lemoine E, Guery EA, Rollin J, Gruel Y, Pouplard C. Thromb Haemost. 2019 Jul

• Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Yu JK, Iorio A, Edginton AN; WAPPS co‐investigators. Collaborateur: Pr. Y. GRUEL Res Pract Thromb Haemost. 2019 May 20
• Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia. Kizlik-Masson C, Deveuve Q, Zhou Y, Vayne C, Thibault G, McKenzie SE, Pouplard C, Loyau S, Gruel Y, Rollin J. Blood. 2019 May 30
• Bleeding risk for patients with haemophilia under antithrombotic therapy. Results of the French multicentric study ERHEA.Desjonqueres A, Guillet B, Beurrier P, Pan-Petesch B, Ardillon L, Pineau-Vincent F, Sigaud M, Fouassier M, Ternisien C, Gillet B, Béné MC, Horvais V, Lienhart A, Trossaërt M. Br J Haematol. 2019 May;
• Etiology and Outcomes of Thrombotic Microangiopathies. Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, Mérieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Buchler M, Vigneau C, Fakhouri F, Halimi JM. Clin J Am Soc Nephrol. 2019 Apr
• Fibronectin: a “double hit” modulator in HIT? Gruel Y, Rollin J. Blood. 2019 Feb 28
• Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications: Proposals from the French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Thrombosis and Haemostasis (GFHT), in collaboration with the French Society for Anaesthesia and Intensive Care (SFAR). Godier A, Garrigue D, Lasne D, Fontana P, Bonhomme F, Collet JP, de Maistre E, Ickx B, Gruel Y, Mazighi M, Nguyen P, Vincentelli A, Albaladejo P, Lecompte T; French Working Group on Perioperative Haemostasis (GIHP). Arch Cardiovasc Dis. 2019 Mar
• Factor VIII assays in treated hemophilia A patients. Lasne D, Pouplard C, Nougier C, Eschwege V, Le Cam Duchez V, Proulle V, Smahi M, Harzallah I, Voisin S, Toulon P, Sobas F, Galinat H, Flaujac C, Ternisien C, Jeanpierre E; groupe d’études de la biologie des maladies hémorragiques du Groupe français d’études de l’hémostase et la thrombose. Ann Biol Clin (Paris). 2019 Feb
• Factor IX assays in treated hemophilia B patients. Pouplard C, Jeanpierre E, Lasne D, Le Cam Duchez V, Eschwege V, Flaujac C, Galinat H, Harzallah I, Proulle V, Smahi M, Sobas F, Ternisien C, Toulon P, Voisin S, Nougier C; groupe d’études de la biologie des maladies hémorragiques du Groupe français d’études de l’hémostase et la thrombose. Ann Biol Clin (Paris). 2019 Feb